Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting  Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) --...

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE...